Abstract |
This study was performed to determine whether a highly selective nonpeptide alpha(v)beta(3) antagonist ( SH306) would prove effective in inhibiting neointima formation in a rabbit cuff model. The animals were dosed with SH306, 5 mg/kg i.v., followed by 10 mg/kg s. c., 3 times daily for 3 days, or with vehicle (10% DMAC). Rabbits were sacrificed and perfused on days 1, 3, and 21; the vessels were paraffin embedded. A reduction in the intima/media (I/M) of the SH306-treated rabbits, as compared with the vehicle-treated control group, was noted (0.20 vs 0.36 [n = 4]). A significant increase in the area of the media was observed in the SH306-treated group versus the control group (0.20 vs 0.13). No difference was observed in cell proliferation between SH306 and vehicle after 1-day and 3-day dosing. Thrombi were found in 43% of the control vessels and in only 14% of the drug-treated vessels. No anticoagulant was used during the surgical procedure. No increase in inhibition of GPIIb/IIIa was observed in SH306-treated animals, as compared with the vehicle control group. We conclude that selective inhibition of alpha(v)beta(3) reduced neointima formation in a rabbit model at 3 weeks.
|
Authors | A L Racanelli, S K Gibbs, K L Schlingmann, M H Corjay, P K Jadhav, T M Reilly |
Journal | Journal of cellular biochemistry
(J Cell Biochem)
Vol. 77
Issue 2
Pg. 213-20
(Mar 2000)
ISSN: 0730-2312 [Print] United States |
PMID | 10723088
(Publication Type: Journal Article)
|
Copyright | Copyright 2000 Wiley-Liss, Inc. |
Chemical References |
- Platelet Glycoprotein GPIIb-IIIa Complex
- Pyridines
- Receptors, Vitronectin
- SH 306
|
Topics |
- Animals
- Cell Adhesion
(drug effects)
- Cell Division
(drug effects)
- Endothelium, Vascular
(drug effects, pathology)
- Femoral Artery
(drug effects, injuries, pathology)
- Humans
- In Vitro Techniques
- Male
- Platelet Aggregation
(drug effects)
- Platelet Glycoprotein GPIIb-IIIa Complex
(metabolism)
- Pyridines
(pharmacology)
- Rabbits
- Receptors, Vitronectin
(antagonists & inhibitors)
|